Story thread · 3 reports / 3 sources
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharmadive.com · 5h · first report
How the coverage leans
Across 3 sources · syndicated copies counted once
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.